The selected candidate(s) will work in the laboratory of Jianqin Lu of Pharmaceutical Sciences in Pharmaceutics and Pharmacokinetics, College of Pharmacy (Ranked #16 in US), The University of Arizona (ranked #73 globally by U.S. News & World Report, and a member of the Association of American Universities, a distinction to only 62 North America's premier research institutions).
The overarching goal of the Lu lab is to apply synthetic chemistry, nanoparticle engineering, and tumor immunology to develop efficacious nanotherapeutics to address the pressing unmet needs in current cancer therapy. The current research focuses on developing efficacious cancer immunotherapy via nano-enabled immuno-engineering through concurrently inducing immunogenic cell death and reversing immunosuppressive tumor microenvironment (e.g. Immune checkpoints). Dr. Lu was the recipient of the Norman R. and Priscilla A. Farnsworth Award at School of Pharmacy, University of Pittsburgh, and USHHS Ruth L. Kirschstein Institutional National Research Service Award in Tumor Immunology among others. He has published 24 research articles, 1 book chapter, and 2 patent applications (One has been licensed) as well as been the invited speaker in the prestigious 41st Controlled Release Society Annual Meeting & Exposition.
One postdoc position is available immediately.
Candidate will focus on drug/gene/protein/peptide delivery/nanomedicine (liposome, emulsion, polymeric and core-shell nanoparticles), in vitro and in vivo characterizations and therapeutics studies.